<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409263</url>
  </required_header>
  <id_info>
    <org_study_id>1943/2017</org_study_id>
    <nct_id>NCT03409263</nct_id>
  </id_info>
  <brief_title>Austrian Registry on Transjugular Intrahepatic Portosystemic Shunts</brief_title>
  <acronym>AUTIPS</acronym>
  <official_title>Österreichisches Register (Inklusive Biobank) für transjuguläre Intrahepatische Portosystemischem Shunts (TIPS): AUTIPS (AUstrian TIPS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Reiberger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with TIPS will be recruited in this prospective registry study. The clinical course
      will be documented and biomarkers for prediction of complicatiosn will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with advanced chronic liver disease may develop portal hypertension, which is the
      main cause for most complications and deaths of patients with liver cirrhosis. Implantation
      of a transjugular intrahepatic portosystemic shunt (TIPS) leads to instantaneous alleviation
      of portal hypertension, but may cause hepatic encephalopathy. Stent grafts, as well as
      patient stratification and medical surveillance, have drastically improved over the past
      decades. However, there are few data on long-term outcome after TIPS implantation.This
      prospective registry study will assess the clinical course of patients after undergoing TIPS
      intervention and biomarkers for complications after TIPS implantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Transplant-free survival</measure>
    <time_frame>0-10 years</time_frame>
    <description>Assessment of transplant-free survival after TIPS implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of portalhypertensive complications</measure>
    <time_frame>0-10 years</time_frame>
    <description>Documenting the incidence of portalhypertensive complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of hepatic encephalopathy</measure>
    <time_frame>0-10 years</time_frame>
    <description>Documenting the incidence of hepatic encephalopathy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Portal Hypertension</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>Not applicable (observational registry study)</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood probes (collected during routine blood draws): Serology (auto-antibodies), chemistry,
      hematology, coagulation panel Ascites: WBC, RBC, protein Urine: WBC, RBC, protein, sediment
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients or outpatients who are scheduled for TIPS implantation, or who have recently
        undergone TIPS implantation and are visiting outpatienc clinics for control
        visits/surveillance
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-99 years

          -  Portal hypertension

          -  Anticipated or past implantation of a transjugular intrahepatic portosystemic shunt
             (TIPS)

          -  Informed consent

        Exclusion Criteria:

          -  Retraction of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Reiberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Reiberger, MD</last_name>
    <phone>01 40400 47440</phone>
    <phone_ext>+43</phone_ext>
    <email>thomas.reiberger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Theresa Bucsics, MD</last_name>
    <email>theresa.bucsics@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Reiberger, M.D.</last_name>
      <phone>+43140400</phone>
      <phone_ext>47440</phone_ext>
      <email>thomas.reiberger@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Bucsics, M.D.</last_name>
      <phone>+43140400</phone>
      <phone_ext>65890</phone_ext>
      <email>theresa.bucsics@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Mattias Mandorfer, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Schwabl, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Scheiner, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Reiberger, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theresa Bucsics, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Thomas Reiberger</investigator_full_name>
    <investigator_title>Assoc.-Prof. Priv.-Doz. Dr.</investigator_title>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Advanced chronic liver disease</keyword>
  <keyword>Ascites</keyword>
  <keyword>Variceal hemorrhage</keyword>
  <keyword>Transjugular intrahepatic portosystemic shunt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data may not be shared publicly due to local data safety regulations. Please contact the sponsor for more information.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

